Is NMN better than NR for longevity?

The honest answer is that the human evidence does not support a confident ranking. Both compounds raise blood NAD+ levels. The downstream effects on health and aging biomarkers have been inconsistent across small trials. No human trial of either compound has measured lifespan or hard clinical outcomes. NMN has a more eye-catching rodent literature; NR has slightly more total human trial reps and a cleaner regulatory standing.

Why is NMN sometimes hard to find on Amazon?

FDA has stated that NMN does not meet the legal definition of a dietary supplement because it was investigated as a drug (Metro International Biotech's IND filing) before being marketed as a supplement. Retailers including Amazon have periodically pulled NMN products in response to FDA correspondence and warning letters. The supplement industry contests FDA's interpretation, and CRN filed a citizen petition, but FDA's position has not been overturned. NR does not have this issue.

Will taking NMN or NR make me live longer?

There is no human trial showing either compound extends lifespan or reduces all-cause mortality. The 'longevity supplement' framing comes from rodent studies (where modest lifespan extension has been shown in some mouse strains) and from the hypothesis that age-related NAD+ decline contributes to age-related dysfunction. The hypothesis is plausible. The human evidence currently shows that NAD+ rises and that downstream effects on function are small and inconsistent over 6-12 week trials.

What dose is studied in the human trials?

NR: most commonly 250-500 mg/day in published trials, with safety data up to 1,000-2,000 mg/day. NMN: most commonly 250 mg/day in the published trials, with safety data up to 1,000 mg/day. Higher doses have not been shown to produce proportionally larger effects in the existing literature.

Over 6 to 12-week trial windows at the doses studied, both appear safe and well-tolerated in healthy adults. Common reported side effects are mild (occasional GI upset, headache). Longer-term safety data (years to decades of continuous use) does not exist for either compound. People with cancer, on chemotherapy, or with other conditions affecting NAD+ metabolism should talk to their oncologist or physician before starting either, since NAD+ has roles in DNA repair and cell signaling that could matter in those contexts.

What about NAD+ IV drips or injectable NAD+?

IV NAD+ is offered at wellness clinics, often at high cost ($300-$1,000+ per session). The human evidence for IV NAD+ as a longevity intervention is even thinner than the oral precursor evidence. The pharmacokinetics are different (IV bypasses oral absorption entirely), and the cost-per-NAD+ delivered is dramatically higher. The case for IV NAD+ as a longevity treatment is not supported by published trials.

Should I take NR or NMN if I am over 50?

If you have decided to take one of them with realistic expectations, both are reasonable choices. The Martens 2018 NR trial and the Igarashi 2022 NMN trial both enrolled middle-aged and older adults and showed safe NAD+ elevation. Functional benefits in those trials were small and inconsistent. The single highest-yield 'longevity' intervention in the 50+ literature is not NAD+ precursors; it is resistance training, adequate protein, sleep, and cardiovascular fitness. Supplements are a small lever next to those.

Is the David Sinclair / Harvard research enough to justify NMN?

David Sinclair's lab has produced influential rodent research on NAD+ precursors and sirtuin biology. His public communication around NMN has been more confident than the human evidence base supports. Sinclair is also co-founder of Metro International Biotech, the company whose IND filing triggered FDA's drug-exclusion ruling on NMN, which is a relevant disclosure when evaluating his public commentary on the compound. The lab work is real and interesting; the marketing claims that downstream of it have run ahead of the data.

NMN vs NR for Longevity (2026): What the Research Actually Shows

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) sit at the top of the longevity supplement category in 2026, with a combined market in the high hundreds of millions of dollars and YouTube and podcast coverage that treats them as established science. The actual evidence base is much thinner than the marketing suggests, and the honest answer to "which one is better for longevity" is "we do not yet have data that supports a confident answer for either."

This piece walks through what NAD+ precursors actually do, what the human trials have measured (and what they have not), the pharmacokinetic and regulatory differences between the two compounds, and how to think about the spend if you are going to take one anyway. The framing is deliberately cautious. The supplement industry's framing on NAD+ precursors has gotten well ahead of the data, and the post is structured around that gap rather than around picking a winner.

The NAD+ Longevity Thesis (In Plain Language)

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme used in essentially every cell in the body to drive energy metabolism, DNA repair, and signaling through proteins called sirtuins and PARPs. Blood and tissue NAD+ levels decline with age. In rodents, restoring NAD+ via precursor supplementation improves a long list of biomarkers (insulin sensitivity, mitochondrial function, exercise capacity) and modestly extends median lifespan in some specific mouse models.

The longevity hypothesis is that the age-related NAD+ decline is causal, or at least contributory, to age-related decline in function. If you can restore NAD+ pharmacologically, you may slow or partially reverse those processes. This is a coherent, plausible hypothesis. It is not, in 2026, a hypothesis with strong human outcome data behind it.

How NMN and NR Differ Biochemically

Both are precursors that get converted to NAD+ in cells. The salvage pathway typically runs:

Nicotinamide riboside (NR) → nicotinamide mononucleotide (NMN) → nicotinamide adenine dinucleotide (NAD+)

NMN is one step closer to NAD+ in this pathway, which is the marketing case used by NMN brands. The counter-case from the NR side is that NMN may not cross cell membranes intact; the prevailing biochemistry suggests that oral NMN is partly hydrolyzed to NR (or further to nicotinamide) before being taken up by cells, then reassembled inside. If that is correct, both products may largely funnel through similar pathways in vivo, and the "one step closer" argument is misleading. There are competing labs on both sides of this debate (the Imai group at Washington University has produced most of the NMN pharmacokinetic work; the Brenner group has been a vocal counterpoint). The honest current answer: NAD+ blood levels rise with either compound, and the upstream specifics are still being argued in the primary literature.

What the Human Trials Actually Show

This is where the gap between marketing and evidence is largest. The clinical data on both compounds is dominated by small (n=10 to 40), short (6 to 12 weeks), biomarker-focused trials. No human trial of either compound has measured lifespan, all-cause mortality, or a hard clinical outcome like incident cardiovascular disease.

Nicotinamide riboside (NR)

Martens et al. 2018, Nature Communications: 6-week RCT in healthy middle-aged and older adults. NR was well-tolerated and raised whole-blood NAD+. Cardiovascular and metabolic endpoints showed small directional effects (modest reductions in systolic blood pressure) but no large clinical signals.
Remie et al. 2020, AJCN: 6-week RCT, 13 overweight or obese subjects, 1,000 mg NR daily. Increased fat-free mass by about 1.34%, raised muscle acetylcarnitine, raised resting metabolic rate slightly. Critically, the study found no significant effects on insulin sensitivity, mitochondrial function, cardiac function, blood pressure, or inflammation. This is one of the better-designed NR trials and the metabolic-improvement story did not replicate.
Several smaller trials and a handful of safety/pharmacokinetics studies (Conze, Trammell, Dollerup, Dolopikou) have shown that NR raises NAD+ in blood and skeletal muscle in a dose-dependent way, is well-tolerated up to 1,000-2,000 mg per day, and does not produce hard adverse events over the trial windows tested.

Nicotinamide mononucleotide (NMN)

Yoshino et al. 2021, Science: 10-week RCT in 25 prediabetic, overweight or obese postmenopausal women. NMN at 250 mg/day improved muscle insulin sensitivity (insulin-stimulated glucose disposal) versus placebo. This is the single most-cited NMN trial and the strongest mechanistic human result either compound has produced. The sample size is small, the population is narrow (prediabetic postmenopausal women), and the outcome is a biomarker, not a clinical event.
Igarashi et al. 2022, NPJ Aging: 12-week RCT in 20 healthy older men (10 NMN, 10 placebo) at 250 mg/day. Raised blood NAD+. Improved gait speed and left grip strength. No significant effect on body composition, glucose control, or insulin sensitivity. The functional improvements are interesting but the sample is small and the authors call for larger trials.
Several other small NMN trials (Liao, Yamane, Pencina) have shown safe NAD+ elevation across doses from 250 mg to 2,000 mg per day. None have powered for hard outcomes.

What both literatures have in common

NAD+ rises. This part is robust across compound, dose, and trial.
Safety appears reasonable over 6-12 weeks at standard doses (typically 250-1,000 mg/day).
Downstream effects on function, body composition, glucose control, cardiovascular markers, and inflammation are inconsistent. Some trials show small effects; many show none.
No trial has measured a clinical event endpoint (mortality, cardiovascular event, diagnosed disease) or has followed participants long enough to credibly do so.
The Yoshino 2021 Science paper and the rodent literature dominate the marketing. The negative or null human trials do not.

If you have read NMN or NR marketing and come away thinking the human data supports a meaningful effect on healthspan or aging biology, the marketing has overstated what the trials measured. The trials measured blood biomarkers in small samples over short windows. They did not test the longevity hypothesis directly, and no current trial design will.

The Regulatory Situation (The Part the Marketing Skips)

This is where NMN and NR genuinely diverge, and it is the most under-discussed difference between them.

NR has straightforward dietary supplement status.

NR (sold most prominently as NIAGEN by ChromaDex) was self-affirmed as Generally Recognized as Safe (GRAS) for use in conventional foods and has been marketed as a dietary supplement in the United States since roughly 2013. NIAGEN holds a New Dietary Ingredient (NDI) notification accepted by FDA. The product is on solid regulatory ground as a supplement.

NMN's status is contested.

In 2022, FDA responded to industry inquiries (from CRN, AHPA, and others) about NMN's status by stating that NMN had been investigated under an Investigational New Drug (IND) application before being marketed as a supplement. Under the FD&C Act drug-exclusion clause at 21 U.S.C. 321(ff)(3)(B), a substance that was the subject of substantial clinical investigation as a drug, and for which that investigation was made public, is excluded from the definition of a "dietary supplement" unless it was marketed as a supplement (or food) first. The IND in question was filed by Metro International Biotech, a company co-founded by longevity researcher David Sinclair.

The supplement industry has pushed back. CRN filed a citizen petition arguing that FDA's interpretation was wrong, and FDA has reiterated its position. As of 2026, NMN remains in regulatory limbo: it is widely sold, but FDA's stated position is that it does not meet the legal definition of a supplement, and the agency has issued warning letters to specific NMN brands over disease claims and labeling. The legal exposure of any individual brand depends on how aggressively FDA chooses to enforce; the agency has been selective rather than systematic.

Practically, this matters in three ways for a consumer:

The cGMP and quality oversight that should apply to dietary supplements may be applied unevenly to a product the agency considers not to be one. Third-party testing matters more than usual for NMN.
The same dispute means international availability and Amazon-platform policies have been inconsistent over the last 18 months. Some retailers periodically pull NMN; others continue to sell it.
For people who value regulatory clarity in their supplement choices, NR has a meaningfully cleaner picture today than NMN.

Cost and Practical Dosing

Standard doses in the human trial literature:

NR: 250-1,000 mg/day. Most studied at 250-500 mg.
NMN: 250-1,000 mg/day. Most studied at 250 mg.

Typical 2026 pricing for third-party-tested product at research-grade doses runs $40-$80 per month for either compound. NIAGEN-branded NR (the form used in most published trials) commands a premium. Generic NMN from Amazon ranges from cheap-and-unverified to expensive-and-tested.

If you decide to spend the money on either, third-party testing is more load-bearing than the brand argument. NSF, USP, ConsumerLab, or Informed Sport verification is the floor. For NMN specifically, the 2022-2024 testing literature (independent reviews by ConsumerLab and others) found high variability in actual NMN content versus label claim. Some products contained substantially less NMN than advertised. Some contained primarily nicotinamide. For a category where the underlying evidence is already weak, paying for a verified product matters disproportionately.

What This Adds Up To

The most honest summary of NMN vs NR in 2026:

Both raise blood NAD+ in humans. This is the strongest result either compound has.
Both have weak downstream evidence. Small trials, short windows, biomarker endpoints, no longevity outcomes.
NR has the cleaner regulatory standing and more total human trial reps. NMN has the single best mechanistic human result (Yoshino 2021) but a contested regulatory status that the marketing rarely mentions.
Neither has been shown to extend human healthspan or lifespan. The framing of NAD+ precursors as "longevity drugs" relies on extrapolation from rodent studies and a hypothesis that has not been tested in humans with the kind of trial that could falsify it.
The category is not a scam, but it is over-marketed. $40-$80 per month on a supplement with weak human outcome data is a reasonable choice for someone who wants to bet on an emerging hypothesis with their own money. It is not a reasonable choice if you are buying it because you read a podcast claim that it would add years to your life.

If you are going to pick one anyway, the case for NR rests on cleaner regulatory standing, slightly more total trial reps, and the longer track record of NIAGEN-branded product as the form used in most published research. The case for NMN rests on the Yoshino 2021 result (which is the best mechanistic human result either compound has) and on the lab buzz around NMN as the more direct NAD+ precursor. Both are defensible if you go in clear-eyed about how thin the human evidence still is.

The Bottom Line

NMN and NR are interesting compounds with weak human evidence in 2026. NAD+ levels rise. Almost everything downstream from that is either a small biomarker effect, a null result, or an extrapolation from rodent data. Both compounds are safe over the trial windows tested. NR has clean dietary supplement status; NMN's status is disputed by FDA and the agency's position has not been overturned. If you spend money on either, treat the spend as a bet on an unproven hypothesis, not as evidence-based health insurance.

The category will look different in 2030, when the larger trials currently in flight (NIH-funded NR trials, several private-sector NMN programs) read out. Until then, anyone telling you that a specific NAD+ precursor is "the" longevity supplement is selling something, not summarizing the evidence.

Sources

Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 29599478.
Remie CME, Roumans KHM, Moonen MPB, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am J Clin Nutr. 2020;112(2):413-426. PMID: 32320006.
Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596.
Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging. 2022;8(1):5. PMID: 35927255.
FDA correspondence on NMN regulatory status (2022-2023). Cited statutory provision: FD&C Act 201(ff)(3)(B); 21 U.S.C. 321(ff)(3)(B).

NMN vs NR for Longevity in 2026: What the Research Actually Shows